Aims: To investigate factors associated with prescribing of the Extended Release Buprenorphine (XR-BUP) injectable Buvidal, and patient rated changes in outcome variables. 
Design: Cross-sectional analysis of anonymised electronic records from patients receiving Buvidal vs. traditional Opioid Agonist Therapy (OAT). To examine predictors of receiving Buvidal (vs OAT) we conducted logistic regression. Psychological Health, Physical Health and Quality of Life scores were analysed using Welch’s t-tests. In adjusted models we conducted linear regressions including the demographic predictors (age, employment, ethnicity, age of first substance, number of episodes, gender and IMD).  
Setting: Data was analysed from a national substance use treatment provider Via, with data from six Via integrated substance misuse services included in our analyses.